Early Feasibility Studies (EFS) give medtech innovators the chance to evaluate a medical device in real clinical settings long before committing to large or expensive trials. These early-stage studies typically involve a small number of patients and limited investigational sites, but the insights they generate are incredibly valuable.
The goal of early feasibility studies is to gather preliminary clinical data about safety, usability, and basic device performance. Because designs are still evolving at this stage, researchers can make iterative changes based on real feedback from clinicians and patients. This flexibility helps identify potential usability issues, refine device features, and guide technical improvements long before full-scale development.
One of the biggest advantages of early feasibility studies is the ability to reduce risk. Instead of investing heavily in formal pivotal trials without practical data, developers can make evidence-based decisions earlier, improving confidence in both the design and the regulatory pathway.
For medtech startups, early feasibility studies are not only a scientific tool—they are a strategic milestone. By learning from early human use, companies can minimize costly redesigns, accelerate development, and strengthen their chances of successful clinical adoption and regulatory approval later in the process.
